Intex Pharma BPC-157 10mg

What is Intex Pharma BPC-157?

Intex Pharma BPC-157 is a pharmaceutical grade synthetic peptide containing Body Protection Compound 157, a 15-amino acid sequence originally isolated from human gastric juice by Croatian researchers in 1993. Each vial contains 10mg of lyophilised BPC-157 powder for subcutaneous injection following reconstitution with bacteriostatic water. BPC-157 is one of the most widely researched healing peptides in the sports recovery and longevity space, with a substantial body of preclinical evidence for tendon and ligament repair, gut lining restoration and anti-inflammatory activity. Available from the Intex Pharma shop at £40.00 with same day UK despatch.

The majority of BPC-157 research to date is preclinical, conducted in animal models. Human clinical trials are limited. The evidence base is genuinely compelling in multiple tissue types but should be understood as strong preclinical data rather than completed human trial confirmation. This is the honest characterisation of the current research status.

How Intex Pharma BPC-157 works

BPC-157 acts through several interconnected mechanisms rather than a single receptor pathway. This multi-mechanism profile is what makes it applicable across multiple tissue types and is why its effects in animal models span tendons, gut lining, muscle, nerve and bone.

Applications for bodybuilders and athletes

Intex Pharma BPC-157 is used primarily in the bodybuilding and performance community for two distinct applications. The first is musculoskeletal injury recovery, particularly tendon and ligament injuries that are slow to heal due to poor vascularity. The second is gut health, where the combination of high-protein diets, NSAID use, and oral anabolic compound use creates an environment that damages the intestinal lining over time.

A 2025 study published in NIH PMC confirmed that BPC-157 therapy produced consistent healing effects across all time points in a rat quadriceps detachment model, with macroscopic, microscopic, ultrasonic, MRI and biomechanical assessments all showing recovery effects that were absent in untreated controls. The study used both oral and injectable BPC-157, with the injectable form producing the most direct localised results and the oral form producing systemic effects through gut absorption.

BPC-157 is also commonly stacked with TB-500 (Thymosin Beta-4) for compounded soft-tissue recovery. The two peptides target different repair pathways and their effects are considered complementary rather than redundant.

How to reconstitute Intex Pharma BPC-157 10mg

BPC-157 must be reconstituted with bacteriostatic water before use. Do not use plain sterile water. Bacteriostatic water contains benzyl alcohol which preserves the reconstituted peptide for up to 30 days when refrigerated.

Dose reference at 5mg per ml concentration

Dosing protocols

For tendon and ligament injury

250 to 500mcg injected subcutaneously once or twice daily. For localised tendon or ligament injuries, injection close to the affected site delivers BPC-157 to the target tissue more directly. Systemic subcutaneous injection into the abdomen also produces results for tendon healing through circulating peptide reaching the injury site. Most research protocols run four to eight weeks for acute injuries, with two weeks off before reassessing.

For gut health

250 to 500mcg taken orally on an empty stomach. BPC-157 has direct activity on the intestinal epithelium when taken orally because this is its native biological environment. Oral use for gut-targeted applications is supported by animal model research on gastric ulcers, IBD-like conditions and intestinal permeability. A four to six week oral course is the typical protocol for gut health applications.

For systemic recovery

250 to 500mcg injected subcutaneously once daily into the abdomen. This protocol is used for general tissue repair and recovery support rather than targeting a specific injury. It is also the approach used when stacking with TB-500 for compounded soft-tissue effects.

Side effects

BPC-157 has a well-established safety profile in animal models. At doses used in research protocols, no significant toxicity has been observed. The most commonly reported effects in human use are mild and injection-site related.

• Injection site reactions. Mild redness, warmth or swelling at the injection site. Rotating sites reduces this.
• Nausea. Reported by some users at higher doses. Usually transient and dose-dependent.
• Dizziness. Occasionally reported, particularly at initial use. Usually resolves within minutes.
• No hormonal disruption. BPC-157 does not alter testosterone, GH or IGF-1 levels. It does not require PCT. It can be used alongside any anabolic compound without pharmacological conflict.

Frequently asked questions about Intex Pharma BPC-157